Checkpoint inhibition for early-stage hormone receptor-positive breast cancer
- Published on 07/04/2024
- Reading time: 4 min.
Ilana Schlam a,b , Chiara Corti c,d,e,f,g , Sarah Sammons c,d,e , Elizabeth A. Mittendorf d,e,h & Sara M. Tolaney c,d,e,*
a Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA
b School of Medicine, Tufts University, Boston, MA, USA
c Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
d Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, USA
e
Harvard Medical School, Boston, MA, USA
f Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
g Department of Oncology and Hemato-Oncology (DIPO), University of Milan, Milan, Italy
h Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA
CONTACT Sara M. Tolaney mailto:sara_tolaney@dfci.harvard.edu Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
Abstract
Introduction Most patients with breast cancer have early-stage hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative disease. Even though the prognosis for most of these patients is good, there is a need to identify patients at risk for poor outcomes and to develop strategies to mitigate this risk.
Areas covered The addition of immunotherapy to standard neoadjuvant chemotherapy represents a promising option for select...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
